Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal

Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT06218810 by Fudan University, with a registry enrolment figure of 53 participants, started 2024-01-01 and due to reach its primary completion in 2025-12-31. Interventions recorded: Cadonilimab + bevacizumab + FOLFOX. Conditions listed: Metastatic Colorectal Cancer; Microsatellite Stable Colorectal Carcinoma; RAS Mutation; Cadonilimab. Primary outcome: 1-year Progression Free Survival rate. Colorectal eligibility wording from the registry: "Subjects diagnosed with metastatic colorectal adenocarcinoma by histology or cytology". Sites: China. No results are recorded here; the registry entry is the source.